Medicon Hellas S.A (MEDIC) Fair Value & Analysis
Healthcare · GR · Market cap €12.7M
Fair value as of: Jul 24, 2026
From 26 valuation models · updated 17 days ago
Fair value updated Jul 24, 2026, revised from €10.76 to €8.22 (−23.6%) since Jun 25, 2026. Share price −6.2% over the past month.
A solid business, screening 200% undervalued on our models.
What matters now
- The price is below even our cautious bear case (€4.17). The market is more pessimistic than our downside scenario.
- The model range is unusually wide (€4.17 to €12.04). The outcome hinges heavily on assumptions, so read the point estimate with caution.
- Solid quality (54/100) at a price below fair value, the discount is the argument here, not the business quality.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 24, 2026.
How to read this chart
60‑month range €1.75 – €4.96 · fair‑value band €4.17 – €12.04 · the €2.74 price screens below the €8.22 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 24, 2026.
Analysis
Medicon Hellas S.A (MEDIC) currently trades at €2.74, while our model-based Fair Value estimate is €8.22, implying the stock looks roughly 200.0% undervalued today. The Quality Score stands at 54/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, Medicon Hellas S.A generated revenue of €18.0M at a net margin of 9.7%. Revenue declined 6.0% year over year. It earns a return on equity of 9.2%. The stock trades on a trailing P/E of 16.8. Fundamentals as of Jul 24, 2026
Our scenario range runs from €4.17 (bear case) to €12.04 (bull case); at €2.74, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 8% below its 52-week high and 25% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 200%, MEDIC screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Multiples (€10.67) versus Dividend Discount (€0.2700). Highest evidence: Growth DCF (80).
Notify me when MEDIC reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 24, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 53 · Market factors (momentum, volatility) 64
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Medicon Hellas S.A. operates in the diagnostics industry. The company offers instruments, tests, and procedures for public and private hospitals, primary care centers, diagnostic centers, and private laboratories in Greece and internationally.
Full company description
Medicon Hellas S.A. operates in the diagnostics industry. The company offers instruments, tests, and procedures for public and private hospitals, primary care centers, diagnostic centers, and private laboratories in Greece and internationally. The company distributes various analyzer sysytem for chemistry, immunochemistry and hematology labs, intensive care units, and point-of-care systems. It also produces reagents for various analyzers, such as specific protein and hematology, as well as clinical chemistry reagents comprising control and calibration materials, and tests. In addition, the company engages in the production of cosmetic and skin care products under the Miss Beaute brand name. Further, it develops and sells software for laboratory and medical applications, and supplies IT systems to healthcare providers. Additionally, the company remanufactures and resells chemistry, hematology, blood gas, and immunochemistry analyzers; and provides contract remanufacturing and diagnostics laboratory services. Medicon Hellas S.A. was founded in 1988 and is headquartered in Gerakas, Greece.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2018 – FY2022 · reported fiscal years
Medicon Hellas S.A reported revenue of €20.8M in FY2022 versus €13.8M in FY2018, a compound +10.8%/yr. Reported net income was €2.5M in FY2022, compounding +8.5%/yr from FY2018.
Watch MEDIC: get an alert when its fair value changes →
Peer Group
Drug Manufacturers - Specialty & Generic · 624 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.19 | ¥25.94 | -51% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,933 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹7,316 | ₹1,943 | -73% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,763 | ₹1,329 | -72% |
| PharmaEssentia Corporation 6446 | 1,285 TWD | 221.01 TWD | -83% |
| Cipla Limited CIPLA | ₹1,439 | ₹1,001 | -30% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,151 | ₹703.32 | -39% |
| Lupin Limited LUPIN | ₹2,443 | ₹2,477 | +1% |
| Mankind Pharma Limited MANKIND | ₹2,484 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,211 | ₹874.79 | -28% |
Compare Medicon Hellas S.A with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Medicon Hellas S.A (MEDIC) overvalued or undervalued?
What is the fair value of MEDIC?
What is the quality score of MEDIC?
What is the revenue of Medicon Hellas S.A (MEDIC)?
What is the net profit margin of MEDIC?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Medicon Hellas S.A and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.